CNSX:LXX - Lexaria Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.69 -0.04 (-2.31 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.73
Today's Range$1.61 - $1.71
52-Week Range$0.27 - $2.54
Volume43,505 shs
Average Volume250,001 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.

Receive LXX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Packaged Foods
SectorConsumer Defensive



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Lexaria Bioscience (CNSX:LXX) Frequently Asked Questions

What is Lexaria Bioscience's stock symbol?

Lexaria Bioscience trades on the CNSX under the ticker symbol "LXX."

What price target have analysts set for LXX?

1 Wall Street analysts have issued 12-month target prices for Lexaria Bioscience's stock. Their forecasts range from $3.50 to $3.50. On average, they expect Lexaria Bioscience's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 107.1% from the stock's current price. View Analyst Price Targets for Lexaria Bioscience.

What is the consensus analysts' recommendation for Lexaria Bioscience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexaria Bioscience in the last year. There are currently 1 strong buy rating for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for Lexaria Bioscience.

Has Lexaria Bioscience been receiving favorable news coverage?

Media coverage about LXX stock has trended neutral recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Lexaria Bioscience earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the near future.

Who are some of Lexaria Bioscience's key competitors?

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexaria Bioscience investors own include KushCo (KSHB), MGX Minerals (XMG), Crispr Therapeutics (CRSP), Beleave (BE), Namaste Technologies (N), Gevo (GEVO), Micron Technology (MU), Protech Home Medical (PHM), Kintavar Exploration (KTR) and Hydropothecary (THCX).

Who are Lexaria Bioscience's key executives?

Lexaria Bioscience's management team includes the folowing people:
  • Mr. Christopher A. Bunka, Chairman & CEO (Age 57)
  • Mr. John M. Docherty, Pres & Director (Age 50)
  • Mr. Allan Spissinger, CFO, Corp. Sec. & Treasurer (Age 50)
  • Mr. Alex Blanchard, Mang. Corp. Communications & Investor Relations
  • Dr. Edward Ergenzinger, Chief Legal Officer & Sr. VP of Innovation

How do I buy shares of Lexaria Bioscience?

Shares of LXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexaria Bioscience's stock price today?

One share of LXX stock can currently be purchased for approximately $1.69.

What is Lexaria Bioscience's official website?

The official website for Lexaria Bioscience is

How can I contact Lexaria Bioscience?

The company can be reached via phone at 250-765-6424.

MarketBeat Community Rating for Lexaria Bioscience (CNSX LXX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Lexaria Bioscience and other stocks. Vote "Outperform" if you believe LXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel